Results 101 to 110 of about 15,382 (226)

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 990-1004, July 2026.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

American journal of hematology/oncology, 2020
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and thrombosis.
Carlos M. de Castro, F. Grossi, I. Weitz, J. Maciejewski, Vivek Sharma, E. Roman, R. Brodsky, L. Tan, Carl Di casoli, D. El Mehdi, Pascal Deschatelets, C. Francois   +11 more
semanticscholar   +1 more source

Early‐Onset Mucocutaneous Findings and Isolated Progressive Thrombocytopenia in a Child With a DKC1 A353V Variant

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Dyskeratosis congenita (DC) is a rare telomere biology disorder characterized by mucocutaneous abnormalities and progressive bone marrow failure. We report a 10‐year‐old boy with a hemizygous DKC1 c.1058C > T (p.Ala353Val) variant who presented with unusually early mucocutaneous findings, including oral leukoplakia at 2 years of age, followed ...
Harun Kasapoğlu, Aslı Turgutoğlu Yılmaz, Berkin Berk Akbeyaz, Neslihan Çalışkan, Yılmaz Ay   +4 more
wiley   +1 more source

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria

Drugs in R&D
Background and Objective Paroxysmal nocturnal hemoglobinuria is a rare blood disorder characterized by life-threatening hemolysis and thrombosis. Complement C5 inhibitor therapy improves symptoms and life prognosis; however, it can result in insufficient
Ryan L. Crass, Brandon Smith, Sven Adriaens, Sunny Chapel, Grant Langdon   +4 more
doaj   +1 more source

Necrotizing Fasciitis in Paroxysmal Nocturnal Hemoglobinuria

Case Reports in Hematology, 2015
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive, and life-threatening hematopoietic stem cell disorder characterized by complement-mediated intravascular hemolysis and a prothrombotic state.
Pusem Patir, Yakup Isik, Yigit Turk, Mehmet Can Ugur, Cengiz Ceylan, Gulnur Gorgun, Nihal Mete Gokmen, Guray Saydam, Fahri Sahin   +8 more
doaj   +1 more source

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

Frontiers in Immunology, 2019
The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed,
A. Risitano, S. Marotta, P. Ricci, L. Marano, C. Frieri, F. Cacace, M. Sica, A. Kulasekararaj, R. Calado, P. Scheinberg, R. Notaro, R. Peffault de Latour   +11 more
semanticscholar   +1 more source

Paroxysmal Nocturnal Hemoglobinuria Superimposed with Preeclampsia

Taiwanese Journal of Obstetrics & Gynecology, 2006
Objective: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement-mediated intravascular hemolysis. As maternal complication of PNH is already severe, it becomes much more complex when preeclampsia is ...
Mann-Ling Chen, Chen-Hsiang Yu, Fong-Ming Chang, Pao-Lin Kuo   +3 more
doaj   +1 more source

Outcomes of dengue infection in adults with underlying haematological diseases in Brazil during 2024 and 2025

British Journal of Haematology, Volume 209, Issue 1, Page 324-328, July 2026.
K. Tozatto‐Maio, V. Weihermann, C. W. Erthal, M. W. Araújo, C. R. Gomes, K. Caciola, L. Otuyama, J. Gasparini, H. R. Higashino, S. F. Costa, A. N. Duarte‐Neto, F. S. Seguro, P. R. Villaça, E. D. R. P. Velloso, S. F. M. Gualandro, Y. Nukui, V. Rocha   +16 more
wiley   +1 more source

Paroxysmal nocturnal hemoglobinuria and thrombosis

Акушерство, гинекология и репродукция
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematopoiesis disorder caused by a somatic mutation in the PIGA (phosphatidylinositol glycan, class A) gene, resulting in deficiency of glycosylphosphatidylinositol (GPI)anchored ...
A. R. Khisamieva, A. R. Oskolkova, V. O. Bitsadze, J. Kh. Khizroeva, N. A. Makatsariya, M. V. Tretyakova, N. R. Gashimova, K. N. Grigoreva, D. V. Blinov, J.-Ch. Gris, I. Elalamy, G. Gerotziafas, A. D. Makatsariya   +12 more
doaj   +1 more source

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1303-1304, June 2026.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source